JP2025510539A5 - - Google Patents
Info
- Publication number
- JP2025510539A5 JP2025510539A5 JP2024552041A JP2024552041A JP2025510539A5 JP 2025510539 A5 JP2025510539 A5 JP 2025510539A5 JP 2024552041 A JP2024552041 A JP 2024552041A JP 2024552041 A JP2024552041 A JP 2024552041A JP 2025510539 A5 JP2025510539 A5 JP 2025510539A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- residue
- fab
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305242.4 | 2022-03-02 | ||
| EP22305242 | 2022-03-02 | ||
| PCT/EP2023/055243 WO2023166098A1 (en) | 2022-03-02 | 2023-03-01 | Bispecific antibodies binding to her-3 and to either her-2 or egfr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510539A JP2025510539A (ja) | 2025-04-15 |
| JP2025510539A5 true JP2025510539A5 (enExample) | 2026-02-27 |
Family
ID=80930221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552041A Pending JP2025510539A (ja) | 2022-03-02 | 2023-03-01 | Ｈｅｒ－３に及びｈｅｒ－２又はｅｇｆｒのいずれかに結合する二特異性抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250282892A1 (enExample) |
| EP (1) | EP4486774A1 (enExample) |
| JP (1) | JP2025510539A (enExample) |
| KR (1) | KR20240154641A (enExample) |
| CN (1) | CN119451982A (enExample) |
| AU (1) | AU2023228330A1 (enExample) |
| CA (1) | CA3244947A1 (enExample) |
| TW (1) | TW202342538A (enExample) |
| WO (1) | WO2023166098A1 (enExample) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| EP2282769A4 (en) * | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| BR112013003257A2 (pt) | 2010-08-10 | 2016-06-14 | Glycotope Gmbh | anticorpos egfr humanizados. |
| EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| JP5786839B2 (ja) | 2012-12-05 | 2015-09-30 | 株式会社デンソー | エポキシ樹脂組成物および接着構造体の製造方法 |
| JP7014724B2 (ja) * | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリンおよびその使用 |
| WO2020136566A1 (en) | 2018-12-24 | 2020-07-02 | Sanofi | Multispecific binding proteins with mutant fab domains |
-
2023
- 2023-03-01 JP JP2024552041A patent/JP2025510539A/ja active Pending
- 2023-03-01 KR KR1020247032358A patent/KR20240154641A/ko active Pending
- 2023-03-01 WO PCT/EP2023/055243 patent/WO2023166098A1/en not_active Ceased
- 2023-03-01 CA CA3244947A patent/CA3244947A1/en active Pending
- 2023-03-01 EP EP23709174.9A patent/EP4486774A1/en active Pending
- 2023-03-01 CN CN202380025034.3A patent/CN119451982A/zh active Pending
- 2023-03-01 AU AU2023228330A patent/AU2023228330A1/en active Pending
- 2023-03-01 US US18/842,834 patent/US20250282892A1/en active Pending
- 2023-03-02 TW TW112107660A patent/TW202342538A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP4477579B2 (ja) | 抗体の軽鎖スクリーニング方法 | |
| CN102239182B (zh) | Muc1*抗体 | |
| JP2013510164A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2025160226A5 (enExample) | ||
| CA2782016C (en) | Monospecific polypeptide reagents | |
| CN116964084A (zh) | 双特异性抗体 | |
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JP2024507693A5 (enExample) | ||
| TW202222824A (zh) | Egfr結合複合物及其製備和使用方法 | |
| JPWO2022224997A5 (enExample) | ||
| US9777072B2 (en) | Protein complex and method of preparing same | |
| CN121522173B (zh) | 一种检测a型肉毒毒素ha-70的检测方法及产品 | |
| US12269895B2 (en) | Method for improving affinity of antibody for antigen and use thereof | |
| WO2019216436A1 (ja) | 抗体の抗原結合領域を含み、生理活性ペプチドを融合する人工タンパク質 | |
| WO2019077951A1 (ja) | Ｍｕｃ１に対する抗体またはその抗原結合断片、それらのコード遺伝子、およびその用途 | |
| CN111440239A (zh) | 抗人转化生长因子β1的纳米抗体B3及其制备方法和应用 | |
| CN119998326A (zh) | 具有新型二硫键的超稳定抗体片段 | |
| CN110642947A (zh) | 抗人cd147的单克隆抗体、表达载体、细胞株及其应用 | |
| JP2023513512A5 (enExample) | ||
| JP2023178884A (ja) | 膜タンパク質のＣ末端に付加したＨｉｓ－ｔａｇに対する高親和性モノクローナル抗体 | |
| RU2019134211A (ru) | Устойчивые мультиспецифические антитела | |
| CN119874928A (zh) | 基于免疫化学发光法的全能核酸酶残留检测试剂盒 | |
| KR101559479B1 (ko) | 고감도 바이오센서용 다가항체 |